Share Name Share Symbol Market Type Share ISIN Share Description
Positive Healthcar 6% Bds 31/01/21 GBP1 NEX:DOC NEX Common Stock GB00BYSZ9K78
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.00 0 -
Bid Price Offer Price High Price Low Price Open Price
0.00 0.00 0.00 0.00 0.00
Last Trade Time Trade Type Trade Size Trade Price Currency
- 0 0.00 GBX
Positive Mental Health Limited ("PHML"), the wholly-owned operating subsidiary of the Positive Healthcare PLC ("Positive" or the "Company"), is an established business in the healthcare recruitment business.

PMHL was established in 20 February 2014 and operates in the healthcare recruitment sector in England and recruits mental health doctors, nurses and carers exclusively, including psychologists (all talking therapies), psychiatrists, community nurses and registered mental nurses. The niche in which PMHL operates lies within the Allied Health Professions (AHP) sector of the NHS and private hospitals. The Company's Directors intend to grow PMHL at a manageable pace and ultimately cover additional niches within the Allied Health Professionals sector.

The Directors intend to expand its family of healthcare recruitment businesses to form a group that provides a full range of recruitment services to the NHS and other healthcare customers. In so doing, the Company's Directors intend to create a business with strong brand loyalty, an efficient operating structure and over time a group which becomes a major player in the healthcare recruitment market.

Positive Healthcar 6% Bds 31/01/21 GBP1 (DOC) Latest News

Real-Time news about Positive Healthcar 6% Bds 31/01/21 GBP1 (NEX): 0 recent articles
More Positive Healthcar 6% Bds 31/01/21 GBP1 News
Positive Healthcar 6% Bds 31/01/21 GBP1 Takeover Rumours

Positive Healthcar 6% Bds 31/01/21 GBP1 (DOC) Discussions and Chat

Positive Healthcar 6% Bds 31/01/21 GBP1 Forums and Chat

Date Time Title Posts
07/2/201311:10the-doc's post library103
12/11/201014:59Doctor Doctor who the F@ck am I2
12/2/201013:09Test thread-
28/9/200714:07Can anyone help the_doctor?16
12/7/200513:12Documedia 2005 - E-commerce digital print provider386

Add a New Thread

Positive Healthcar 6% Bds 31/01/21 GBP1 (DOC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Positive Healthcar 6% Bds 31/01/21 GBP1 trades in real-time

Positive Healthcar 6% Bds 31/01/21 GBP1 (DOC) Top Chat Posts

the_doctor: Quite a spike in volume there, with several million shares suddenly traded in the days before that refinancing was due to be completed! The share price rose around 30% as a result ---------------------------------------------- photo sharing websites ---------------------------------------------- jt 27 Mar'11 - 06:44 - 24 of 26551 0 0 POSTED AT 5:25 PM ON 16th MAY 2011. QUINTILES RE-FINANCING BACK ON TRACK In previous posts no's 22 and 23 I discussed the strong likelihood that the presence of Quintiles at PRM's AD Focus day was not just a coincidence, together, and supported by their strong involvement and history over 5 years in Alzheimer studies throughout the world (ref post 23, Quintiles presentation pdf file), I pointed to the likelihood that in my opinion that there may be a deal to come in the future and this may be predicated by the large re-financing package that Quintiles reported via a press release on 23rd March. The re-financing as of Wednesday 11th April is now back on track and should be completed by 7th June; see one of just several news reports on Wednesday this week including live report on Bloomberg TV. We are not there yet but it is timely nevertheless to consider what comes next and for shareholders to see the big picture that may arise in a shorter time frame than might be expected. Many will be surprised to know that the big pharmacos often take a copycat attitude to drug development. A case in point was the rush into gamma secretase inhibitors of beta amyloid plaque because they believed en-mass that if you could stop or remove beta amyloid then Alzheimer's disease would be cured or stopped in its tracks. With so many notable beta amyloid failures, see just one of them, post 23 and reference to Quintiles involvement with Eli Lilly and the failed gamma secretase enzyme inhibitor compound (pill form) semagacestat, pharmacos (including their CRO counterparts) are now turning their attention to tau tangles. A deal with the world's largest CRO around AD would alert big pharmacos to Proteome and its position in Alzheimer's. The significance will primarily hit home with each of the large drug companies that Proteome are already engaged. It is these companies and others that will shape the direction of Proteome's share price as they turn their attention to the patented technology held by Proteome and the in-depth knowledge being acquired by Proteome's partner that will spell-out a head start into a new regime of drug testing. It will inevitably lead to similar deals with Proteome at the centre of negotiations. Quintiles may potentially become the CRO AD expert of choice and will benefit from their greater expertise and ability to cherry pick subsequent AD pharma partners and programmes. With colossal budgets, see yesterday's 12th May proposed buy-out by Takeda of Swiss rival Nycomed for $12 billion, it will only take one company to start a bidding war for Proteome with the primary focus being to catch up on the missed Alzheimer deal opportunity and at the same time to play catch up again by attempting to acquire the IP rights to the multiple Alzheimer's patents held by Proteome. It's not rocket science guesswork and also not difficult to see multiples of the current share price being reached in a short time frame. To fully understand the full significance of the deal 'in the wings' ponder for a moment the huge costs that have to be ear-marked for a full human clinical study. Upwards of $200 / $500 million are spent on the phase 3 pivotal study so this sort of monetary commitment must be there from the outset and a lot more of course to cover expenses up to phase 3 and beyond in companion diagnostic monitoring of the new drug. When a company first files to take a compound from pre-clinical testing into human trials, the FDA now require the submission of credible biomarker programme data. It should go without saying that the game changer deal will be the result of pre-clinical selective monitoring of several compounds during which Proteome's 9 panel will have been extensively used to evaluate suitable candidates to take forward into clinical trials. A deal could not follow without such in-depth investigational work. From Proteome's standpoint their inclusion in a clinical trial will show just how highly considered their technology and experience is being rated and there can be no greater pointer to what comes next.
dibbs: Topvest good luck with the profit and move onwards. Indeed profit is not profit untill realised by sale of shares. Finbarr have to think about new thread title, we have time before deal is finalised. I know that the market is much more than just us ADVFN guys, However gaining some investor interest is usefull. I guess its a fine line between sounding like a cheap "ramping" thread or on the other hand a uninspiring stock with no bull points. Agree with Safman that the tech, quality of management, growth prospects, niche products and blue chip clients should stand out. Whilst wishing Topvest the best of on his sale, I have no plans to sell at this stage. I made the mistake with ASC of getting out too early having entered at a very keen price. I have always viewed DOC as a "multi-bagger" prospect and although the market cap will grow with the new shares I think that DOC will gain plenty from the deal to more than compensate thus allowing plenty of room for further share price growth. It will be interesting to see what the weekend press and next few weeks reveal, exciting times indeed for DOC holders. Enjoy the weekend. Dibbs
yump: topvest I know exactly what you mean about initial hype etc. Would have done the same as you except that its one of the few takeovers that I've seen that hasn't had a load of hype from the companies and the fit actually looks logical and the takeover well planned, not empire building. Difficult to know exactly what earnings DOC can bring in per contract, but am certain that the growth of the Documarketing side will now be much more rapid because of access to May still take a bit out and leave the 'partly free' money behind. Just intrigued that the price went up so much yesterday and it wasn't the result of press coverage. Anyone know where that 300,000 pre-tax quote came from ? Working backwards, say 10mln turnover this year (conservative) must be able to generate 500,000 pretty soon in this sort of business, especially if some overheads disappear. That would give about 0.5p per share, p/e 20 which kind of looks middling to me. Future is what interests me though - as with most small stocks in high growth areas - looking for jumps in earnings that make each previous years share price look cheap.
yump: This looks like one of the few takeover actions that I've seen that make complete sense and don't seem to involve a load of spin. Looks like this to me: Tangent / LDP want to float and want to be in the forefront of their field. DOC have a special technology which is now proven - I've yet to see any others. DOC not large enough to expand at the rate they want and also not the easiest or quickest of jobs trying to break into blue chip client 'circle'. End result, DOC get immediate access to lots of blue chip clients and their agencies. LDP get an immediate competitive advantage over any competitors by virtue of having a unique? offering in their portfolio. I particularly liked this bit: "Operators that contain similar 'back office' facilities with modern 'on-line' technology are few" So I think we are still in a growth company at the leading edge, which is why I bought DOC in the first place. (Its not some big company swallowing up a tiddler and taking my shares ex-growth). But don't ask me what the share price should be !
yump: Still here, happy to hold and look once a week or so. I've always liked the step-type charts. Stake builders and no traders. News better, company growing, share price not moved much - I always like to think that means there's a kind of pent up pressure behind the share price IF it goes, I reckon it could be a vertical job.
dibbs: Saffy and Topvest, I'm still here too, not much to add. I Continue to hold and share your views re potential growth for DOC. At least the price has not fallen as per many small cap shares. DOC's time has not yet come. I was in ASC as per Saffy from 4.88p when their was no investor interest. For months the price was static and no one cared for the co. The results for ASC showed strong growth and the share price remained range bound, the rest is history. DOC's share price growth needs a catalyst and this is what we lack. I think that the market will react at some point and then in a big way. I guess its just the way of the market, no recognition followed by a herd of tips, hype, investors and traders. By that time the price will probably be OTT but we will be a lot richer! Patience will, I hope be rewarded. Happy waiting Dibbs
safman: Courtesy of davethehorse .. on the TPA thread... another stock in the print management industry... Buy TripleArc at 20.75p Argues Rob Cullum, editor of TrendWatch In the latest issue of TrendWatch, I recommended TripleArc, an online web-based print procurement services company. By Wednesday of this week, it had risen just shy of 17% before falling back somewhat on Thursday. The price rise prompted a statement from the company. More of that later. TripleArc floated on AIM in December 2001 at 30p. It links buyers and suppliers of print services via internet-based workflow software known as CWS (Collaborative Workflow System). CWS handles the job initiation, print design, tendering, acceptance, and even online delivery of the printing, with the ability to check on the job status at any time. Its potential market is estimated at 1.2bn pounds a year, with 15% annual growth. It has access to the giant US market via marketing partners, including Hewlett-Packard and the oddly named Four51. These partners distribute TripleArc's software to US-based print management companies, thus generating additional licensing revenue for TripleArc. The company has got where it has today not only because it has good products, but also by swallowing its competitors, large and small. The small one, in the shape of ControlP, was snapped up with petty cash: 0.25 million pounds to be exact. Then, in November 2003, it paid 40 million pounsd for its much bigger rival Access Plus. As a result, TripleArc now claims to be UK's largest provider of e-commerce solutions for the print management industry, and the fourth-largest print management company overall. TripleArc's print management division has now been renamed Access Plus. The reverse takeover gave it the critical mass it needed to be able to chase the big contracts. It reflects great credit on the management of both companies, especially Access Plus, that they recognised the logic of the deal. Access Plus had a good geographic spread of local offices, which TripleArc lacked. But Access Plus recognised that it lacked TripleArc's advanced technology solution. So this was a good fit. Note that we're not talking about run-of-the-mill printing here. We're talking about BIG stuff. Such as the 1.5 million pounds a year contract to supply the print requirements of hospital operator BMI Healthcare; or the 10 million pounds p.a. contract from BAA; or the 5 million pounds p.a. contract from Malalan, to name but three recently-won contracts. On advantage of taking over Access Plus was that it moved TripleArc into the enormous area of junk. sorry - direct mail. Access Plus is capable of project-managing all aspects of a direct mail marketing campaign, a high margin business. TripleArc's interims are due out on 11 September. We expect them to be impressive. In fact, thanks to the takeover of Access Plus, we expect it to make more money in the first 6 months than it made in the whole of the previous year. House broker Altium Securities is enthusiastic and bullish about the company, and has a price target of 30p, nearly 50% above the current share price. We're not surprised. The share price seems to have completely lost the plot. TripleArc's turnover all but tripled between 2002 and 2003. Normalised earnings of 0.53p in 2003 are forecast to double to 1.05p this year, then to surge another 40-odd percent to 1.5p in 2005. Yet the shares are on a 2005 p/e of 13.1, in line with the Support Services sector. With this rate of growth, they deserve to be trading at a big premium to the sector. Another reason that the shares are undervalued is that TripleArc's business model throws off masses of cash. Altium reckons that as much as 50% of EBITA will be converted to free cash flow, which should swiftly reduce the 70% gearing. Altium believes that the print management industry is on the verge of substantial growth. Large companies will increasingly outsource their print management function because TripleArc can do the job more cheaply and more efficiently. With its integrated and focused technology solutions, few service providers are as well qualified as TripleArc to capitalise on that growth. Right on cue, the company announced last Wednesday that it had noted the strengthening share price and confirmed that it had been given preferred bidder status for a significant print management outsourcing contract. The shares are overdue for a re-rating. September's interims may be the catalyst that triggers it. BUY. DTH "Altium believes that the print management industry is on the verge of substantial growth." .. saffy
safman: fin.. it will be interesting to see what DOC have to say... if they are profitable .. it will be a big boost to the company (historically they have been loss making)... clearly showing that their model is working well.. and extending their bluechip client base.. the reason why the share price is as it is, because there has been little news... but the potential is definatly there.. not a lot of ppl know about DOC so any profits from this company will have a big swing upside in share price ... that may not be initially, but i can def see it... when the company decides to raise its profile or is tipped ... that will help the share price . at the moment we are still embryonic (in terms of updates /news)... and remember the mkt cap is only 2.2 mill.. for an internet based tech stock stock in growth mkts .. its one of those that has not been noticed... but u quietly keep adding at these levels... saffy!
yump: Just read that. So DOC share price absorbed the sale and actually rose.
safman: DOCUMARKETING - THINK GLOBAL, ACT LOCAL - over 15000 users Documedia Technology - Documarketing (Update 22nd Nov) This share is certainly worth looking at. Its technology is interesting as it uses Internet powered tool to generate personalised sales and marketing collateral for the finance, leisure, Retail and Property Sector. The technology is very effective: and is described by the CEO as"Best of Breed" in a recent Interview. In the print industry.. digital print is the fastest growing sector, and is set to grow rapidly to 2008 - combine that now with an e-commerce method of printing, i.e. web print.. in DOC's terms, documarketing .. then that is simply huge. Mkt cap - 1.96 mill Turnover 8.0 mill Assets - London/cheltenham./ Dir Buys 1 mill shares in company No. Of employees - 71 Perhaps more Importantly, they have announced a series of 8 new and existing contracts that may be worth 500K+ each so far this year. Clients include Proctor and Gamble, Alpha Systems, House of Frasier, Inventive Lesuire etc. A Little History and a Recent Interview with the CEO at the Wall St Reporter. May 2004 ( a pdf version transcript) - Was one of those Start-ups.. - 3/4 yrs loss making - albeit.. and reduced levels.. last results showed a 70% improvement - BUT NOW CEO HAS ACKNOWLEDGED THE BUISNESS IS CASH-GENERATIVE - T/O 8-8.5 MILL - Revenues from Outsourcing, 60% of revenues is generated from online technology - The Differentiating factor - DOC says its offerings differ from its competitors as it - offers a complete solution rather than parts dictated by its competitors CEO Mark O Conner " the marketing world has long yearned for a solution like documarketing and we have brought our knowledge of the Internet, document management and print production together to provide this innovative product". Saffy: Documedia have themselves a good product ..lots of corporate activity so far in 04.. a far cry from 03..and now cash generative.. They are now generating a lot of revenue from online technology / Documarketing ... i have this as a buy capped at 1.2 mill.. the share price could well touch 8-10p+ yr end results out Jul 4th last yr.. so not long to go.. Clients include: Green King (500+ pubs), Strutt and Parker, Kodak, Boshe, Monsson, alpha retail, Nomura, TRA, CAA, ACCA, BT, Citreon, RA, Inventive Leisure, Procter and Gamble, Wolverhamton and Dudley (500+ pubs), House of Frasier, Phillips...etc The Future? "We have technology partners based in both in Europe and in Boston. We have the very best of people on the sales piece and on the back office delivery piece. So, we are comfortable about that. We are recognized by some of our much larger competitors who have parts of these offerings as really genuinely functioning above our weight. And for an £8 million turnover company to beat some UK competitors with turnovers of over $200 million to $250 million, to beat them on the final run in some big project wins, has been an exciting experience in the last year." " I am really excited about getting that full and then holding that at as our centre of excellence and then exploiting opportunities outside of the UK for our licensed on line platform, software & consultancy. We are talking to two marketing companies in the US and Australia right now to explore how our ASP solution can help them win major league marketing contracts. Update 22th NOV 04 - highlights - rollout of documarketing to 438 outlets of Laurel pubs acquired by Greene King (over 1000 pubs now), rollout of documarketing to 275 Citreon outlets, many of the above contracts live, ANOTHER POSSIBLE 7 CONTRACTS IN THE PIPELINE - losses reduced by 50% - not yet profitable but now a recovery play. To understand how documarketing works.. (how to obtain digital print solutions online) visit their simulations Chairman Warren Taylor holds approx 30% of documedia solutions. Documedia prides itself on being UK's leading 'on demand' digital print specialist, providing innovative online automated creation and fulfilment of high impact localised in-store marketing solutions, through 'documarketing™'.
Positive Healthcar 6% Bds 31/01/21 GBP1 share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Positive H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200811 17:20:33